Inclusion Criteria

Eligibility Criteria:

- Metastatic and/or locally advanced GIST, with diagnosis based on histology with
positive c-kit and/or DOG-1, or with a GIST-typical mutation in KIT or PDGFR

- Measurable disease on CT (computed tomography) as defined by RECIST criteria; at
least one measurable lesion not given radiotherapy

- History of progressive disease on CT according to RECIST criteria after both imatinib
and sunitinib treatment, and also after nilotinib if this drug has been given

- No other TKIs given than imatinib, sunitinib and nilotinib

- Age at least 18 years at the time of diagnosis of GIST

- WHO performance status 0-2

- Resolution of all toxic side effects from earlier TKI treatment and any other
potential non-TKI treatment to grade 1 or below

- Sufficient organ functions as defined in the protocol

- Absence of earlier or present certain other conditions as defined in the protocol

- No pregnancy or lactation

- Women with childbearing potential must accept the use of adequate contraception
throughout the study period

- Written informed consent